Domvanalimab is under clinical development by Arcus Biosciences and currently in Phase III for Gastric Cancer. According to GlobalData, Phase III drugs for Gastric Cancer have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Domvanalimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Domvanalimab is under development for the treatment of non-small cell lung cancer (first line), glioblastoma multiforme (GBM), recurrent glioblastoma multiforme (GBM), esophageal cancer, adenocarcinoma of the gastroesophageal junction, gastric cancer and solid tumor (second line). The drug candidate is administered intravenously. The therapeutic candidate is a monoclonal antibody which acts by targeting TIGIT.
Arcus Biosciences overview
Arcus Biosciences operates as a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Its product pipeline includes AB928, a selective dual antagonist of the adenosine receptors known as A2aR and A2bR in combination with anti-PD-1 antibody (AB122) and chemotherapy is used for the treatment of metastatic triple-negative breast cancer or ovarian cancer and advanced malignancies; AB122, an anti-PD-1 antibody targeting cancer; AB154, an anti-TIGIT antibody; and AB680, a CD73 inhibitor against solid tumors. The company has in-house specialization in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. Arcus Biosciences is headquartered in Hayward, California, the US.
For a complete picture of Domvanalimab’s drug-specific PTSR and LoA scores, buy the report here.